Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease.

The amyloid and tangle cascade hypothesis is the dominant explanation for the pathogenesis of Alzheimer's disease (AD). A complete knowledge of the metabolic pathways leading to beta-amyloid (A beta) production and clearance in vivo and of the pathological events that lead to fibril formation and deposition into plaques is crucial for the development of an 'anti-amyloid' therapeutic strategy. Important advances in this respect have been achieved recently, revealing new candidate drug targets. Among the most promising potential treatments are beta- and gamma-secretase inhibitors, A beta vaccination, Cu-Zn chelators, cholesterol-lowering drugs and non-steroidal anti-inflammatory drugs. Now, the major question is whether these drugs will work in the clinic.

[1]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[2]  P. Ianna,et al.  Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. , 1997, The Biochemical journal.

[3]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[5]  L. Mucke,et al.  TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.

[6]  Masanori Kato,et al.  Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid β-protein (Aβ) deposition , 2001, Brain Research.

[7]  A. Delacourte,et al.  Brain plasmin enhances APP α‐cleavage and Aβ degradation and is reduced in Alzheimer's disease brains , 2000 .

[8]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[9]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[10]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[11]  T. Balaban,et al.  A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[13]  C. Masters,et al.  Rapid induction of Alzheimer A beta amyloid formation by zinc. , 1994, Science.

[14]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[16]  K. Davis,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[17]  Gregory D. Longmore,et al.  γ-Secretase inhibitors repress thymocyte development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[19]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[20]  P. Mcgeer.  Cyclo-Oxygenase-2 Inhibitors , 2000, Drugs & aging.

[21]  M. Folstein,et al.  Nonsteroidal anti-inflammatory drugs in Alzheimer's disease , 1995, Neurology.

[22]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[23]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[24]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[25]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[26]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[27]  M G McInnis,et al.  Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.

[28]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[29]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[30]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[31]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Klein,et al.  Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.

[33]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[34]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[35]  G. Landreth,et al.  Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.

[36]  B. Strooper,et al.  Alzheimer's disease: An inflammatory drug prospect , 2001, Nature.

[37]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[38]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[39]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[40]  P. Mcgeer,et al.  Brain inflammation in Alzheimer disease and the therapeutic implications. , 1999, Current pharmaceutical design.

[41]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[42]  D. Small,et al.  Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.

[43]  Irma-Leena Notkola,et al.  Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease , 1998, Neuroepidemiology.

[44]  A. Igarashi,et al.  Angiotensin-converting Enzyme Degrades Alzheimer Amyloid β-Peptide (Aβ); Retards Aβ Aggregation, Deposition, Fibril Formation; and Inhibits Cytotoxicity* , 2001, The Journal of Biological Chemistry.

[45]  Scott R. Barnum,et al.  INFLAMMATION AND ALZHEIMERS DISEASE , 2000 .

[46]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[47]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[48]  Ruedi Aebersold,et al.  Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing , 2000, Nature.

[49]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[50]  B. Strooper,et al.  Interaction with Telencephalin and the Amyloid Precursor Protein Predicts a Ring Structure for Presenilins , 2001, Neuron.

[51]  S. Scheff,et al.  The Plasmin System Is Induced by and Degrades Amyloid-β Aggregates , 2000, The Journal of Neuroscience.

[52]  C. Haass,et al.  Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch , 2000, Nature Cell Biology.

[53]  Olivier Pourquié,et al.  New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage , 2001, Nature Cell Biology.

[54]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[56]  D. Wilcock,et al.  Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. , 2001, DNA and cell biology.

[57]  P. Scheltens,et al.  Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study , 2001, The Lancet.

[58]  B. Hyman,et al.  Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide , 2001, Nature Cell Biology.

[59]  A. Bigas,et al.  Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. , 1999, Blood.

[60]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[61]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[62]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[63]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[64]  D. Selkoe,et al.  Nasal administration of amyloid‐β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease , 2000, Annals of neurology.

[65]  B. Strooper,et al.  Presenilins and the intramembrane proteolysis of proteins: facts and fiction , 2001, Nature Cell Biology.

[66]  M. Citron,et al.  Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research , 2000, Neuron.

[67]  A. Goate,et al.  Aph-2/Nicastrin An Essential Component of γ-Secretase and Regulator of Notch Signaling and Presenilin Localization , 2002, Neuron.

[68]  R. Perlmutter,et al.  Presenilin-dependent γ-secretase activity modulates thymocyte development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[69]  H. Soininen,et al.  Midlife vascular risk factors and late-life mild cognitive impairment , 2001, Neurology.

[70]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[71]  A. Georgakopoulos,et al.  Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. , 1999, Molecular cell.

[72]  D. Selkoe,et al.  Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase , 2002, Nature Cell Biology.

[73]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[74]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[75]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[76]  H. Saya,et al.  Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway , 2001, The Journal of cell biology.

[77]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.